Galderma Agrees to Buy ZO Skin Health for Around $1.5 Billion, Sources Say

3-line summary

• Swiss skincare company Galderma has agreed to acquire ZO Skin Health for roughly $1.5 billion, according to two unnamed sources cited by Reuters via Investing.com. No official announcement has been made, and both companies did not immediately respond to requests for comment.
• ZO Skin Health was founded in 2007 by dermatologist Zein Obagi and sells cleansers, serums, exfoliants and toners distributed through physicians and skin specialists. Owner Blackstone acquired it in 2020 through its tactical opportunities fund and was reported last month to be exploring a sale with Citigroup and Raymond James.
• Galderma, founded in 1981 and owner of brands including Cetaphil, Alastin Skincare, Differin, Epiduo, Dysport and Restylane (L'Oréal holds a 20% stake), has been pushing to expand in the US market and opened a US/Latin America headquarters in Miami in August. Sources said an announcement could come within days.

This summary is our own processing of the source article; see the source link below for full context.